Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12724731 | 1.00 | TYMP (0.40) | TYMPADORA3ADORA2BADORA1SLC29A1 | |
| SCHEMBL16023740 | 0.92 | TYMP (0.43) | TYMPADORA3ADORA2BADORA1SLC29A1 | |
| SCHEMBL12725200 | 0.90 | TYMP (0.37) | TYMPALDH1A1LMNA | |
| SCHEMBL13360829 | 0.89 | TYMP (0.47) | TYMP | |
| SCHEMBL13329961 | 0.89 | TYMP (0.47) | TYMP | |
| SCHEMBL13213491 | 0.88 | ADORA3 (0.32) | TYMPADORA3ADORA2BADORA1DOT1L | |
| SCHEMBL13213498 | 0.88 | TYMP (0.35) | TYMPADORA3ADORA2BADORA1 | |
| SCHEMBL13213490 | 0.88 | TYMP (0.35) | TYMP | |
| SCHEMBL12724727 | 0.87 | TYMP (0.46) | TYMPADORA1SLC29A1 | |
| SCHEMBL13930532 | 0.87 | TYMP (0.46) | TYMPADORA1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | FUJITSU LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | NSUN2, RNMT, ADAR | TYMP 718/4885ADORA3 825/4885ADORA2B 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.